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Abstract: Methylation of the O6-methylguanine DNA methyltransferase (MGMT) promoter has 
emerged as strong prognostic factor in the therapy of glioblastoma multiforme. It is associated with 
an improved response to chemotherapy with temozolomide and longer overall survival. MGMT 
promoter methylation has implications for the clinical course of patients. In recent years, there have 
been observations of patients changing their MGMT promoter methylation from primary tumor to 
relapse. Still, data on this topic are scarce. Studies often consist of only few patients and provide 
rather contrasting results, making it hard to draw a clear conclusion on clinical implications. Here, 
we summarize the previous publications on this topic, add new cases of changing MGMT status in 
relapse and finally combine all reports of more than ten patients in a statistical analysis based on 
the Wilson score interval. MGMT promoter methylation changes are seen in 115 of 476 analyzed 
patients (24%; CI: 0.21–0.28). We discuss potential reasons like technical issues, intratumoral 
heterogeneity and selective pressure of therapy. The clinical implications are still ambiguous and 
do not yet support a change in clinical practice. However, retesting MGMT methylation might be 
useful for future treatment decisions and we encourage clinical studies to address this topic. 
Keywords: glioblastoma multiforme (GBM); glioma; relapse; temozolomide; MGMT promoter 
methylation; therapy; resistance; recurrence 
 
1. Introduction 
1.1. Epigenetic Changes 
The British scientist Conrad Hal Waddington introduced the term “epigenetics” in the early 
1940s [1]. Since this time the meaning of “epigenetic changes” has been specified and currently is 
understood as heritable changes in gene function, without altering the DNA sequence [2,3]. The DNA 
consists of the four bases adenine, cytosine, guanine, and thymine. After replication, DNA 
methyltransferases can add a methyl-residue to cytosine, forming 5-methylcytosine [4], often 
clustered in palindromic CpG dinucleotides in small areas, the so-called CpG-islands throughout the 
genome [5]. In case such methylated CpG-islands are concentrated in promoter regions, this may lead 
to silencing of the respective genes [6–9]. Although DNA methylation-patterns are considered to be 
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quite stable, it has to be noticed, that the methylation profile can change due to external or internal 
stimuli [7,10]. Indeed, both hyper- as well as hypomethylation do not only play a vital role in long 
term gene regulation, but also in carcinogenesis by reactivating oncogenes, silencing tumor-
suppressor genes, deregulating mRNA expression, promoting mutations or altering the functional 
stability of chromosomes [4,11]. 
1.2. Glioblastoma Multiforme and Gene Methylation 
Methylation patterns play a central role in gliomas. They are not only crucial for the tumor 
subclassification but might also be targeted by novel treatment modalities [12–14]. The current 
standard in the therapy of glioblastoma multiforme (GBM), the most common primary malignancy 
of the central nervous system, includes tumor resection, radiation (RT) and concomitant, as well as 
adjuvant chemotherapy with temozolomide (TMZ) [15]. Although recently the addition of Tumor-
Treating Fields (TTFields) to the therapeutic scheme has shown a great potential to improve patients’ 
outcome, the overall survival (OS) of patients with GBM remains rather unfavorable [16–18].  
Interestingly, in newly diagnosed GBM, methylation of the promoter region of the DNA repair 
enzyme O6-methylguanine-DNA methyltransferase (MGMT) gene has emerged as a strong 
prognostic factor [19-22]. MGMT removes alkyl groups from guanine in the DNA, potentially 
counteracting the therapeutic efficacy of alkylating chemotherapeutics, such as TMZ, in tumor cells 
[23]. Epigenetic silencing of the promoter region of MGMT might lead to transcriptional repression 
and a decreased MGMT protein expression [23]. It is associated with an improved response to TMZ 
chemotherapy and longer overall survival of GBM patients [22,24]. Older patients with MGMT-
promoter methylation benefit from TMZ chemotherapy compared to sole radiotherapy, whereas 
patients without methylation might not [25-28]. Recently, it has been reported that a combination of 
the chemotherapeutic lomustine with TMZ was beneficial solely for GBM patients with methylated 
MGMT promoter, further highlighting the prognostic importance of MGMT promoter methylation 
status determination [29–31]. Nowadays, the patients’ MGMT methylation status is defined by 
methylation-specific PCR (MSP), high-resolution melting PCR (HRM) or pyrosequencing. A cut-off 
value of 8–10% has been acknowledged to distinguish unmethylated from methylated MGMT 
promoters [20,32,33]. 
However, virtually all GBM tend to relapse, usually associated with increasing aggressiveness 
and therapy-resistance [34]. Even though the patients’ general condition or the tumor localization 
often limit the therapeutic approaches in relapse, resection of the recurrent tumor, followed by TMZ-
rechallenge is often a viable option [27,28,35]. Therefore, MGMT promoter methylation might not 
only be predictive for the outcome after primary surgery, but also in tumor recurrence. Nevertheless, 
its role after disease progression and as a predictor concerning the clinical course after secondary 
surgery currently remains unclear [24,36]. 
1.3. Rationale and Methodology 
While working on a study about GBM and their matched recurrences [37], we observed a change 
of MGMT promoter methylation from primary tumor to relapse in some of the GBM patients. These 
observations have not been published so far and are summarized in Figure 1 and Table 1. A Pubmed 
literature search independently conducted by the first and the last author using the keywords 
“MGMT AND glioblastoma AND relapse”, “O6-methylguanine DNA methyltransferase AND 
glioblastoma AND relapse” and “MGMT AND methylation AND change” was performed latest on 
October 30th, 2019. The results were limited to English language studies. Articles on different tumor 
entities, not providing data on MGMT promoter methylation, without information on MGMT 
promoter methylation of primary tumor and relapse or describing unmatched primary tumor and 
relapse samples were excluded. A similar screen of the Web of Science database was carried out, but 
did not yield additional reports of sufficient quality on our topic of MGMT methylation changes in 
gliomas. This work was conducted in accordance with the PRISMA guidelines (Figure A1). Relevant 
citations were screened including cross-references and revealed several publications with similar 
observations as ours. The early data were already reviewed in 2015 [38]. However, in the meantime, 
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several new data have been published, which prompted us to write a new summary of these 
observations. A couple of them were anecdotal or incidental because they had their main focus on 
other topics [39–44]. Others investigated larger patient cohorts to evaluate, whether the re-
determination of the MGMT-methylation status in the relapse situation might be of clinical relevance 
[36,45–54]. Different methods for measuring MGMT methylation and diverse selection criteria have 
been utilized in these reports (Table 2). In addition, some authors came to contrasting conclusions 
and controversially discussed the underlying mechanisms and clinical significance. Here, we 
combine these observations, including our own new data, to get a better overview about this 
interesting and important topic. 
 
Figure 1. Example of two patients (patient 3 and 7) with a change in O6-methylguanine-DNA 
methyltransferase (MGMT) methylation status as determined by high-resolution melting PCR 
(HRM). Shown are the melting curves. The methodology has been described in detail elsewhere [37] 
and is highly accurate compared to methylation-specific PCR (MSP) [55]. (a) Patient 3 had a 
glioblastoma multiforme (GBM) which was methylated between 25% and 50%, while his two relapses 
were unmethylated. (b) Patient 7’s GBM had MGMT promoter methylation between 10% and 25%. 
His relapse was unmethylated. Patients’ details are summarized in Table 1. 
2. Initial and Incidental Observations of MGMT Promoter Methylation Changes 
The first observation of MGMT promoter methylation changes was reported by Komine et al. 
when evaluating the predictive value of MGMT promoter hypermethylation in patients with low-
grade diffuse astrocytomas (LGG) (Table 2) [39]. In a study focusing on the validation of a simplified 
MSP protocol to determine MGMT promoter hypermethylation, Cankovic et al. compared the 
primary tumor and relapse of astrocytic tumors of different grading [40]. Precise information about 
the WHO grading of the tumors or clinical data of the patients is not provided in both studies, due 
to the distinct main focus of the papers. 
Metellus et al. reported an incidental finding of changing methylation status in relapse in GBM 
patients that underwent surgery and carmustine wafer implantation [41]. However, this change 
could only be detected by the MethyLight Technique (cut off: >0%) and was not confirmed by MSP. 
Incidental is also a case report of an epithelial GBM with multiple relapses and methylated MGMT 
promoter, which changed to a typical, unmethylated GBM [42]. The aim of another study was on the 
identification of molecular changes following treatment and recurrence of disease with a particular 
focus on DNA repair pathways [43]. Changes of MGMT promoter methylation were determined by 
pyrosequencing with a cut-off of 13%. Most recently, differences in miRNA expression between 
primary tumor and recurrence have been studied [44]. As a side note, the authors also determined 
MGMT promoter methylation in a subgroup of patients, of which most of the unmethylated samples 
in primary GBM were methylated in recurrent GBM. Unfortunately, no further subgroup analysis is 
provided, since the changes in MGMT methylation were not the main topic of this study. 
Together, these data imply that the MGMT promoter methylation status is not stable during 
disease progression and triggered research on potential clinical implications. 
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Table 1. Summary of patients’ clinical data. 
 Patient characteristics Tumor characteristics Therapy Outcome 
Patient Sex Age 
[years] 
ECOG Tumor 
volume 
[ccm] 
Tumor localization 
[hemisphere/lobe] 
IDH 
mutation 
MGMT promoter 
methylation 
Ki67 
staining 
[%] 
Extent of 
resection 
RT TMZ Relapse OS 
[months] 
PFS 
[months] 
       Primary 
tumor 
Relapse        
1 Female 69 1 33.6 Right/occipital No Negative Negative 20 Subtotal Yes Yes Local 18 3 
2 Female 49 1 25.5 Left/parietal No Positive Positive 35 Subtotal Yes Yes Local 31 15 
3 Male 42 0 54.1 Left/parietal No Positive Negative 30 Subtotal Yes Yes Local 45 12 
4 Female 70 1 9.3 Left/temporal No Positive Positive 10 Subtotal Yes Yes Local 30 3 
5 Female 59 0 8.2 Left/temporal No Positive Positive 20 Subtotal Yes Yes Local 14 4 
6 Male 48 0 58.2 Right/frontal No Positive Positive 30 Total No Yes Local 34 22 
7 Male 66 1 19.1 Left/frontal No Negative Positive 20 Subtotal Yes Yes Local 15 4 
8 Male 58 3 89.9 Right/occipital No Positive Positive 25 Subtotal Yes Yes Multifocal 24 4 
9 Male 49 0 54.8 Left/frontal Yes Negative Positive 30 Total Yes Yes Local 48 6 
10 Male 60 1 79.2 Left/temporal Yes Positive Negative 25 Total Yes Yes Local 25 7 
11 Male 22 3 2.2 Left/frontal Yes Positive Positive 35 Subtotal Yes Yes Multifocal 27 10 
12 Female 47 1 2.3 Left/frontal No Positive Positive 25 Subtotal Yes Yes Multifocal 47 7 
13 Male 74 0 60.7 Left/temporal No Negative Positive 15 Subtotal Yes No Local 12 7 
Total Female: 
5/38.5% 
Male: 
8/61.5% 
Median: 
58 
Median: 
1 
Median: 
33.6 
Left: 10/76.9% 
Right: 3/23.1% 
Frontal: 5/38.5% 
Temporal: 4/30.8% 
Occipital: 2/15.4% 
Parietal: 2/15.4% 
No: 
10/76.9% 
Yes: 
3/32.1% 
Negative: 
4/30.8% 
Positive: 
9/69.2% 
Negative: 
3/23.1% 
Positive: 
10/76.9% 
Median: 
25 
Total: 
3/23.1% 
Subtotal: 
10/76.9% 
Yes: 
12/92.3% 
No: 
1/7.7% 
Yes: 
12/92.3% 
No: 
1/7.7% 
Local: 
10/76.9% 
Multifocal: 
3/23.1% 
Median: 
27 
Median:  
7 
MGMT promoter methylation was determined by high-resolution melting PCR (HRM) with a cut-off value of 10% [37]. Following the recommendations of the World Health 
Organisation [56], immunohistochemical IDH1 R132H negative GBM of patients below the age of 55 years were pyrosequenced for IDH1 and IDH2 mutations. If not stated otherwise, 
all information relate to the time of diagnosis. ECOG: performance status of the Eastern Cooperative Oncology Group; IDH: Isocitratdehydrogenase; MGMT: O6-methylguanine DNA 
methyltransferase; OS: overall survival; PFS: progression-free survival; TMZ: temozolomide.
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3. Systematic Clinical Studies on MGMT Promoter Methylation Changes 
As the first to address variations of MGMT promoter methylation in GBM, Parkinson et al. 
performed a small study (Table 2) [45]. Samples were analyzed not only by MSP but also by promoter 
sequencing, allowing detection of smaller deviations. Gain of methylation was observed in 50% of 
the patients, loss in 20%, while 30% maintained an unmethylated MGMT promoter status in relapse. 
Interestingly, these results differ from 2 out of 4 patients gaining methylation when analyzed by MSP. 
This difference might be due to higher accuracy of promoter sequencing, but also be affected by 
considering a 4% methylated specimen as positive, while the present cut-off value is at 8–10% [20,32]. 
It deserves to be noted that the authors describe a patient with a methylated MGMT promoter in 
primary tumor and recurrence, displaying an increase in the grade of methylation by 28% that could 
not be detected by MSP. 
Christmann et al. examined the interrelation between the MGMT methylation status and MGMT 
activity in GBM patients [46]. Generally, their data show an overall correlation between promoter 
methylation and lacking or low MGMT activity. They also compared primary GBM samples with 
their matched recurrences. It was found that 22% were initially methylated with low MGMT activity. 
One of these tumors displayed reduced and the other one lost MGMT promoter methylation during 
the clinical course, with maintaining and increasing MGMT activity, respectively. Another study, 
evaluating variations of MGMT promoter methylation and protein expression after adjuvant 
treatment in GBM patients came to very similar results [47]. Generally, there was a correlation 
between the methylation status of the MGMT promoter and MGMT protein expression in 65% of the 
analyzed cases. It was found that 33% of recurrent GBM had changed their MGMT promoter 
methylation compared directly to the matched primary GBM from the same patient. A direct, short-
term influence of the therapy on MGMT promoter methylation could not be shown in a cell culture 
experiment. A Japanese research group observed correlation of MGMT mRNA expression with 
MGMT promoter methylation [54]. They analyzed astrocytic tumors WHO grade II–IV, of which 83% 
lost their initial methylation, while the umethylated tumors did not change in relapse. The authors 
speculate that therapy resistant clones or glioma stem cells may survive to form recurrent tumors. 
In a larger study, 37% GBM patients treated with RT and TMZ chemotherapy changed the 
MGMT methylation status in relapse [48]. In 2017, these authors extended their study and found the 
MGMT methylation status to be stable in 75% of the patients [36]. However, seen from another 
perspective, it means that 25% changed their MGMT promoter methylation status. Only patients 
adjuvantly treated with RT and TMZ were included to avoid a potential bias caused by the impact of 
different post-surgical treatments on genetic and epigenetic alterations. Both studies revealed that OS 
was significantly correlated with the MGMT methylation status of the primary tumor, but not at 
relapse, therefore showing no implication towards repetitive MGMT methylation testing in tumor 
recurrence. 
In contrast to previous observations, Felsberg et al. reported a relatively low percentage of 11% 
MGMT promoter methylation changes in relapse, of which they say only 6% can be considered as 
true changes, since their loss or decrease of MGMT promoter methylation at tumor recurrence could 
not be explained by a low tumor cell content of the respective tissue samples [49]. They conclude that 
the MGMT promoter methylation status does not change from primary to recurrent tumor in the vast 
majority of GBM patients and due to this fact they see no implication for repetitive testing in daily 
clinical routine. 
Similarly, Park et al. detected MGMT promoter methylation changes in only 8%, as detected by 
MSP [50]. However, when analyzing 12 of these patients by methylation-specific multiplex ligation 
probe amplification (MS-MLPA), they observed a decrease in the MGMT promoter methylation ratio 
in 75% of the samples). They conclude that such alterations frequently remain undetected in case only 
MSP is utilized. 
O’Regan et al. used pyrosequencing with a cut-off value of 9% for their analysis [51]. While 64% 
of the patients remained stable, 36% changed their methylation status. They hypothesize that such 
changes might be related to TMZ treatment. Although these authors did not find a significant 
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influence of the methylation changes on progression free survival (PFS) or OS of the patients, they 
highlight the need to reappraise the methylation status post-treatment. 
Another study reports a change of the MGMT promoter methylation status in 27% [52]. This 
study is distinctive to the other reports, as the authors took several samples from each individual 
tumor, one from the periphery and another one from the central part. In 80% of all cases the MGMT 
methylation was homogenous throughout the tumor. However, in 20% of the tumors the peripheral 
part was unmethylated, while the central part was methylated and only these initially 
heterogeneously methylated tumors changed their methylation status in relapse. Therefore, the 
authors speculate that this change might be due to clonal expansion of formerly heterogenous tumor 
cells leading to homogenous tumor recurrence. 
The most recent publication on this topic reports patients with astrocytic tumors of different 
WHO grading [53]. Thus, 12 changes in MGMT promoter methylation status could be observed by 
MS-MLPA. However, none of them occured in GBM. Mostly affected were WHO grade III gliomas, 
especially in relation with adjuvant RT, but not with irradiation in combination with chemotherapy. 
Finally, we would like to add our own GBM patients to these studies (Table 1, Table 2). Primary 
tumors and the matched relapses were analyzed by HRM with a cut-off value of 10%. It could be seen 
that 38% had a change in MGMT promoter methylation. Switches occurred into both directions. In 
addition to the global changes described above, HRM allows to detect differences in the grade of 
methylation. Three patients with a positive methylation status in both primary tumor and relapse 
increased their MGMT promoter methylation by at least 20%. Therefore, a total of 62% displayed 
unstable methylation. Three patients presented with a second relapse. However, although in one 
patient the primary tumor was methylated, both of his relapses were unmethylated (Figure 1). The 
other patients had a methylated primary tumor and maintained this status in both relapses. We did 
not detect any correlation of the MGMT promoter methylation status in relapse with the OS of the 
patients. Therefore, our data are consistent with the observations of several authors reviewed above 
in that we do not see a justified clinical implication to re-evaluate the MGMT promoter methylation 
in relapse, yet. 
4. Combined-Analysis 
The main drawback of most of the above-mentioned studies is their small sample size. However, 
if considering all those publications that describe at least 10 patients, together they comprise 476 
patients. In a combined analysis, 115 patients (24%; CI: 0.21–0.28) changed their MGMT promoter 
methylation during the clinical course (Figure 2a). The changes divide into 71 patients (30%; CI: 0.24–
0.36) switching from methylated to unmethylated (Figure 2b) and 44 patients (18%; CI: 0.14–0.24) 
converting from unmethylated to methylated (Figure 2c). 
Main limitations of such a combined analysis are the inhomogeneity of cut-off values, selection 
criteria, utilized methods, and a potential positive publication bias. Additionally, 4 of the included 
studies analyzed not only GBM but also LGG [39,40,53,54]. Therefore, the limitation of our analysis 
derives from such limitations of the original studies. 
5. Potential Reasons for MGMT Promoter Methylation Changes and Their Clinical Implications 
Technical issues, intratumoral heterogeneity and selective pressure of cytotoxic agents are 
discussed as reasons for the observed changes in MGMT promoter methylation during the clinical 
course [36]. 
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Table 2. Summary of publications presenting GBM patients with changes in MGMT promoter methylation in relapse. 
 Patients’ characteristics MGMT-status Therapy Outcome  
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Komine et al. (2003) LGG 14    8 6 11 3 11/3/0      MSP (PE) 
Cankovic et al. (2007) LGG GBM 10    4 6 3 7 7/2/1      MSP (PE) 
Parkinson et al. (2007) GBM 10 8 2 55 3 7 6 4 3/2/5  8/0 9   Promoter sequencing & MSP (FF) 
Metellus et al. (2009)1 GBM 18    6 12 6 12 18/0/0      MSP & methyLight technique (FF) 
Christmann et al. (2010)2,3 LGG GBM 9    2/0 7 1/1 8 7/2/0      MSP (PE) 
Jung et al. (2010) GBM 16 7 9 53 11 5 9 7 11/4/1 15/1/0 14/2 16  19.5 MSP (PE) 
Brandes et al. (2010) GBM 38 28 10 49 13 25 11 27 24/8/6 27/10/1 11/27 38 12.0 24.3 MSP (PE) 
Suzuki et al. (2010) LGG GBM 12 9 3 52 10 2 0 12 2/10/0  1 / 5 5 18.0  MSP (PE & FF) 
Tanaka et al. (2010)2 GBM 1 1 0 55 1 0 0 1 0/1/0 1/0/0 1/0 0   MSP 
Felsberg et al. (2011)3 GBM 80 58 22 57 31/3 49 26/3 54 71/7/2 40/33/6 16/64 56 9.1 18.3 MSP & Pyro- sequencing (FF) 
Park et al. (2012) GBM 24 15 9 60 8 16 8 16 22/1/1  9/14 24 8.0  MSP & MS-MLPA (PE) 
Brandes et al. (2017) GBM 108 69 39 51 54 54 49 59 81/16/11 50/42/16 0/108   24.4 MSP & Pyro- sequencing (PE) 
O’Regan et al. (2017) GBM 22 12 10 50 9 13 7 15 14/5/3  0/22 22   Pyrosequencing (PE) 
Hudson et al. (2018) GBM 19 12 7 60 4 15 2 17 17/2/0  0/19 19 7.0 15.0 Pyrosequencing (FF) 
Matos et al. (2018)4 GBM 47    38 9 46 1 39/0/8   47   MSP (PE) 
Barresi et al. (2018)5 GBM 11 4 7 60 4  10 3 8  11/0/0 11/0/0 0/11 11 16.0 27.0 MSP (PE) 
Harat et al. (2019)6 LGG GBM 45   45 30 15 27 18 33/9/3  14/20    MS-MLPA (PE) 
Own Data GBM 13 8 5 58 9 4 10 3 8/2/3 3/10/0 1/11 12 7.0 27.0 HRM (FF) 
Summary5  485    238 253 229 260 377/64/44       
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If a study used 2 different methods for determining MGMT promoter methylation, only the method with data on more patients was considered in the combined analysis (Figure 2). 1 
This study detected one change by MethyLight technique and none by MSP. 2 These studies were excluded from the combined analysis due to the patient number being below 10. 3 
These studies divided positive promoter methylation status into two groups: all positive tumors vs. weakly positive or hemimethylated. 4 This study only provides the number of 
patients with vs. without methylation at diagnosis and relapse, but does not provide information on individual changes. Therefore, we included the minimal number of changes that 
must have occurred. 5 In Barresi et al. tumor heterogeneity was analyzed, reporting 3 of the primary tumor samples to be methylated in the center and unmethylated in the periphery. 
Therefore, they do not describe a “real change”, but rather a subclonal expansion in tumor recurrence. These tumors were counted as methylated and unmethylated alike. Consequently, 
total numbers do not add up and this study was excluded from the combined analysis. 6 This study distinguished 4 different methylation groups; however, we converted this information 
into “methylated” and “unmethylated”. FF: fresh frozen tissue; GBM: glioblastoma multiforme; HRM: high-resolution melting PCR; LGG: low grade glioma WHO grade I-III; MGMT: 
O6-methylguanine DNA methyltransferase; MS-MLPA: methylation specific multiplex ligation-dependent probe amplification; MSP: methylation-specific PCR; OS: overall survival; PE: 
paraffin-embedded tissue; PFS: progression free survival; RT: radiotherapy; TMZ: temozolomide. 
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Figure 2. Combined analysis of selected data from publications reporting changes in MGMT promoter 
methylation in GBM relapse using IBM SPSS Statistics 25 (IBM, New York, NY, USA). For this analysis 
only studies investigating at least 10 patients were included. In addition, changes were analyzed 
based on the cut-off value of the respective study and not based on the degree of methylation. In case 
MGMT promoter methylation was reported to be analyzed by two or more different methods, we 
focused on the method with the larger number of patients. Only patients with a reported MGMT 
status in the primary tumor and matching relapse were included. Therefore, these data often have 
been extracted from tables or supplementary material published with the respective paper. (a) 
Changes of MGMT promoter methylation in both directions. (b) Loss and (c) gain of MGMT promoter 
methylation. Black squares: percentage of patients with change, loss or gain of MGMT promoter 
methylation; arrows: 95% confidence interval (CI, calculated based on the Wilson score interval, [57]); 
vertical dashed line: overall percentage of MGMT promoter methylation changes from the combined 
analysis of the listed publications. 
MSP is the most widely used method, followed by pyrosequencing, MS-MLPA, MethyLight 
technique and HRM (Table 2) [20]. While MSP allows a methylated/unmethylated classification, the 
other methods provide additional information, e.g. quantification of the grade of promoter 
methylation and its percentual increase or decrease [20]. However, while all these methods are 
established and usually of high accuracy [55], sample quality might be an issue [49]. For example, a 
false negative determination of MGMT promoter methylation by MSP due to necrotic tissue within 
the sample has been reported [58]. Contamination  of  the  tumor  tissue  with  normal  and/or 
inflammatory cells also might lead to an incorrect estimation of the grade of MGMT promoter 
methylation. Felsberg et al. state that approximately half of their observed changes were mainly due 
to low tumor cell content in one of the samples [49]. This questions some of the reviewed data without 
available information about the tumor cell quantity in the analyzed samples. However, only larger 
discrepancies seem to influence the measurement, as tumors differing in tumor cell content up to 40% 
are stated to give comparable results [59]. Therefore, the reported changes might be explained by 
technical inaccuracies only partially, while the majority are not. 
MGMT promoter methylation usually is seen as homogenous within the tumor [45,58,60], 
although some groups reported contrasting results [21,61]. Up to 33% of the GBM were described to 
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be heterogeneous with different MGMT promoter methylation status in the intermediate part of the 
tumor compared to the peripheral and inner parts [61]. This finding is in line with the observations 
by Barresi et al., characterizing 20% of the GBM to be unmethylated at the peripheral parts of the 
tumor, but methylated at the center and only these heterogeneous tumors were the ones changing 
their methylation status in relapse [52]. Therefore, intra-tumoral heterogeneity as a partial reason for 
MGMT promoter methylation changes cannot be excluded and therapy-induced eradication of 
sensitive tumor clones and clonal expansion of resistant ones may be involved in this phenomenon. 
Interestingly, MGMT promoter methylation might not only be predictive for the TMZ-response 
but also altered by it. TMZ treatment may lead to DNA hypermethylation followed by global 
demethylation, raising the question whether TMZ might induce resistance against itself by reshaping 
the methylation pattern [62,63]. Again, the results of the different studies are contradictory. While 
some did not see a correlation between TMZ treatment and a change of MGMT promoter methylation 
[47,49], others drew a different conclusion [48,64]. The subgroup of patients with methylated MGMT 
promoter in the primary tumor displayed a significant loss of methylation if treated with concurrent 
RT/TMZ (7 of 8) compared to patients treated with RT followed by sequential TMZ (1 of 5, p = 0.03). 
Accordingly, the authors discuss whether the type of post-surgical treatment may influence the 
MGMT methylation status [48]. We attempted to perform a subgroup meta-analysis comparing 
patients initially treated with RT only versus patients treated with concomitant radiochemotherapy. 
However, our analysis revealed that the number of patients treated with RT only was insufficient 
and mainly reported by older studies. Therefore, we refrained from presenting these data. However, 
Felsberg et al. tested this hypothesis. Their comparison between patients treated with TMZ and RT 
versus RT alone showed no significant differences in changes of the MGMT promoter status, 
indicating that the observed distinctions were not affected by TMZ treatment [49]. Further, their data 
revealed a correlation between MGMT promoter methylation and OS, as well as MGMT promoter 
methylation at second surgery and post-recurrence survival, diverging from the observations of 
Brandes et al., who detected a significant correlation of MGMT methylation at first and second 
surgery with OS, but not at second surgery with post-recurrence survival [36,48]. The observed 
changes were almost equally distributed to losses (n = 16) and gains (n = 11) of MGMT promoter 
methylation, suggesting TMZ to possibly not be causing a significant selection pressure. This view is 
shared by Storey et al., who recently proposed a mathematical model to predict GBM response to 
TMZ treatment [64]. They conclude that the changes in methylation cannot be explained by 
evolutionary selection alone, but might indeed occur due to TMZ altering the cells’ general 
methylation profile. Although a final conclusion on this topic cannot be drawn, several groups agree 
that there is currently no definitive implication for clinical retesting of the MGMT promoter 
methylation status in the relapse situation [36,49]. 
6. Conclusion 
There are clear indications that the MGMT promoter methylation can change from the primary 
tumor to relapse in about 24% of glioma patients. The possible causes, molecular mechanisms, and 
clinical impacts of these alterations remain ambiguous, with sometimes contrasting results in the 
literature. Recent observations indicate that alterations of the cells’ general methylation profile by 
TMZ might be one important reason for changes of the MGMT promoter methylation status in 
recurrence. This should be further investigated. While there is currently no definitive implication for 
changing the standard of practice or guidelines, our present state of knowledge seems too restricted 
to draw final conclusions. Testing MGMT promoter methylation not only in the primary tumor, but 
also in relapse might be useful. We highly recommend that clinical studies on GBM recurrence 
acknowledge MGMT promoter methylation changes and investigate whether these changes should 
be considered in the treatment decision. 
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Appendix 
 
Figure A1. PRISMA guidelines for methodological review of literature related to MGMT promoter 
methylation changes in glioblastoma relapse. 
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